Remix is working to transform patient's lives through modulation of RNA processing and addressing drug targets in diseases of high unmet medical need. We are a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).
Company Details
- Employees
- 68
- Founded
- 2018
- Address
- 100 Forge Rd, Watertown,ma,ma 02472,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.remixtx.com
- HQ
- Watertown, MA, MA
Remix Therapeutics Questions
Remix Therapeutics's website is https://www.remixtx.com
Remix Therapeutics's LinkedIn profile is https://www.linkedin.com/company/remix-therapeutics
Remix Therapeutics has
68 employees.
View email and phone details for 68
employees at Remix Therapeutics.
Remix Therapeutics's industry is
Biotechnology Research
Remix Therapeutics's top competitors are
Mariana Oncology,
Chimerna Therapeutics,
Kymera Therapeutics,
Moma Therapeutics,
Affini-T Therapeutics,
Tessera Therapeutics,
Orna Therapeutics,
Beam Therapeutics,
Vigil Neuroscience,
Abata Therapeutics.
Remix Therapeutics's categories are Biotechnology Research
Remix Therapeutics's founding year is 2018
